{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:41:49Z","timestamp":1792431709068,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Institute on Drug Abuse Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA013035"],"award-info":[{"award-number":["UG1DA013035"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Institute on Drug Abuse Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA015831"],"award-info":[{"award-number":["UG1DA015831"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.cct.2025.107816","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T19:12:15Z","timestamp":1737400335000},"page":"107816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD)"],"prefix":"10.1016","volume":"150","author":[{"given":"Matisyahu","family":"Shulman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Meyers-Ohki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Provost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Ohrtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Oden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Otterstatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genie L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2025.107816_bb0005","author":"Drug Overdose Deaths | Drug Overdose | CDC Injury Center"},{"issue":"9776","key":"10.1016\/j.cct.2025.107816_bb0010","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.cct.2025.107816_bb0015","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.cct.2025.107816_bb0020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/add.13193","article-title":"Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England","volume":"111","author":"Pierce","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2025.107816_bb0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2017.04.016","article-title":"Relapse to opioid use disorder after inpatient treatment: protective effect of injection naltrexone","volume":"85","author":"Nunes","year":"2018","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2025.107816_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108447","article-title":"Naturalistic follow-up after a trial of medications for opioid use disorder: medication status, opioid use, and relapse","volume":"131","author":"Greiner","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"issue":"2","key":"10.1016\/j.cct.2025.107816_bb0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","volume":"177","author":"Williams","year":"2020","journal-title":"AJP"},{"key":"10.1016\/j.cct.2025.107816_bb0040","author":"NQF: Behavioral Health 2016-2017 Final Report"},{"issue":"10118","key":"10.1016\/j.cct.2025.107816_bb0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cct.2025.107816_bb0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.cct.2025.107816_bb0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.cct.2025.107816_bb0060","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","article-title":"Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial","volume":"174","author":"Liebschutz","year":"2014","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"10.1016\/j.cct.2025.107816_bb0065","doi-asserted-by":"crossref","first-page":"74.e11","DOI":"10.1016\/j.amjmed.2012.07.005","article-title":"A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine","volume":"126","author":"Fiellin","year":"2013","journal-title":"Am. J. Med."},{"issue":"7","key":"10.1016\/j.cct.2025.107816_bb0070","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1176\/appi.ps.201700363","article-title":"Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults","volume":"69","author":"Manhapra","year":"2018","journal-title":"PS"},{"key":"10.1016\/j.cct.2025.107816_bb0075","author":"Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration - Manhapra - 2017 - The American Journal on Addictions - Wiley Online Library"},{"issue":"1","key":"10.1016\/j.cct.2025.107816_bb0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/add.12303","article-title":"Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review","volume":"109","author":"Feelemyer","year":"2014","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.cct.2025.107816_bb0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0477","article-title":"Office-based addiction treatment retention and mortality among people experiencing homelessness","volume":"4","author":"Fine","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.cct.2025.107816_bb0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1360-0443.1988.tb00485.x","article-title":"Reliability of a timeline method: assessing normal drinkers\u2019 reports of recent drinking and a comparative evaluation across several populations","volume":"83","author":"Sobell","year":"1988","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.cct.2025.107816_bb0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/SAR.S239507","article-title":"An updated version of the treatment effectiveness assessment (TEA) [letter]","volume":"11","author":"Ling","year":"2020","journal-title":"Subst. Abus. Rehabil."},{"key":"10.1016\/j.cct.2025.107816_bb0100","author":"Prescribing-information.pdf"},{"issue":"1","key":"10.1016\/j.cct.2025.107816_bb0105","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10550887.2011.642758","article-title":"Effect of buprenorphine dose on treatment outcome","volume":"31","author":"Fareed","year":"2012","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.cct.2025.107816_bb0110","first-page":"2","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cct.2025.107816_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug Alcohol Depend."},{"issue":"11","key":"10.1016\/j.cct.2025.107816_bb0120","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on \u03bc-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.cct.2025.107816_bb0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"J. Subst. Abus. Treat."},{"issue":"1","key":"10.1016\/j.cct.2025.107816_bb0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/add.15115","article-title":"The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine","volume":"116","author":"Farnum","year":"2021","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.cct.2025.107816_bb0135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","article-title":"Leaving buprenorphine treatment: Patients\u2019 reasons for cessation of care","volume":"46","author":"Gryczynski","year":"2014","journal-title":"J. Subst. Abus. Treat."},{"issue":"2","key":"10.1016\/j.cct.2025.107816_bb0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000505294","article-title":"Impact of buprenorphine dosage on the occurrence of relapses in patients with opioid dependence","volume":"26","author":"Reimer","year":"2020","journal-title":"Eur. Addict. Res."},{"issue":"3","key":"10.1016\/j.cct.2025.107816_bb0145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.9740\/mhc.2020.05.080","article-title":"Relapse rates among veterans on maintenance doses of combination buprenorphine and naloxone for opioid use disorder","volume":"10","author":"Binger","year":"2020","journal-title":"Mental Health Clin."},{"issue":"8","key":"10.1016\/j.cct.2025.107816_bb0155","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1185\/03007995.2014.915211","article-title":"Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia","volume":"30","author":"Lafeuille","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.cct.2025.107816_bb0160","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/09540121.2014.967656","article-title":"Medication adherence challenges among HIV positive substance abusers: the role of food and housing insecurity","volume":"27","author":"Surratt","year":"2015","journal-title":"AIDS Care"},{"key":"10.1016\/j.cct.2025.107816_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108492","article-title":"Determinants of interest in extended-released buprenorphine: a survey among 366 French patients treated with buprenorphine or methadone","volume":"220","author":"Rolland","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"7","key":"10.1016\/j.cct.2025.107816_bb0170","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/add.14941","article-title":"Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia","volume":"115","author":"Larance","year":"2020","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.cct.2025.107816_bb0175","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","article-title":"Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study","volume":"34","author":"Albayaty","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.cct.2025.107816_bb0180","author":"Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder - Laffont - 2016 - The Journal of Clinical Pharmacology - Wiley Online Library"},{"issue":"2","key":"10.1016\/j.cct.2025.107816_bb0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cct.2010.01.003","article-title":"A multi-site, two-phase, prescription opioid addiction treatment study (POATS): rationale, design, and methodology","volume":"31","author":"Weiss","year":"2010","journal-title":"Contemp. Clin. Trials"},{"issue":"17","key":"10.1016\/j.cct.2025.107816_bb0190","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol DependenceThe COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2025.107816_bb0195","author":"Counseling plus Buprenorphine\u2013Naloxone Maintenance Therapy for Opioid Dependence | NEJM"},{"issue":"2","key":"10.1016\/j.cct.2025.107816_bb0200","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1037\/1064-1297.16.2.132","article-title":"Computerized behavior therapy for opioid-dependent outpatients: a randomized controlled trial","volume":"16","author":"Bickel","year":"2008","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.cct.2025.107816_bb0205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jsat.2013.08.012","article-title":"Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment","volume":"46","author":"Marsch","year":"2014","journal-title":"J. Subst. Abus. Treat."},{"issue":"6","key":"10.1016\/j.cct.2025.107816_bb0210","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1037\/a0037496","article-title":"Adding an internet-delivered treatment to an efficacious treatment package for opioid dependence","volume":"82","author":"Christensen","year":"2014","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.cct.2025.107816_bb0215","article-title":"Pear therapeutics files for bankruptcy as CEO blames shortfalls on insurers","author":"Jennings","year":"2023","journal-title":"Forbes"},{"issue":"7","key":"10.1016\/j.cct.2025.107816_bb0220","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1176\/appi.ajp.2008.07111835","article-title":"Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT","volume":"165","author":"Carroll","year":"2008","journal-title":"AJP"},{"issue":"4","key":"10.1016\/j.cct.2025.107816_bb0225","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1176\/appi.ajp.2013.13070987","article-title":"Computer-assisted delivery of cognitive-behavioral therapy: efficacy and durability of CBT4CBT among cocaine-dependent individuals maintained on methadone","volume":"171","author":"Carroll","year":"2014","journal-title":"AJP"},{"issue":"1","key":"10.1016\/j.cct.2025.107816_bb0230","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.1993.tb18346.x","article-title":"Saliva testing for drugs of abuse","volume":"694","author":"Cone","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"12","key":"10.1016\/j.cct.2025.107816_bb0235","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1007\/s11136-017-1686-2","article-title":"Selection of key health domains from PROMIS\u00ae for a generic preference-based scoring system","volume":"26","author":"Hanmer","year":"2017","journal-title":"Qual. Life Res."},{"issue":"7","key":"10.1016\/j.cct.2025.107816_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201093","article-title":"Cross-sectional validation of the PROMIS-preference scoring system","volume":"13","author":"Hanmer","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2025.107816_bb0245","author":"CHERISH \u2013 Health Economics Research for HV and HIV Care. CHERISH"},{"key":"10.1016\/j.cct.2025.107816_bb0250","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jsat.2020.02.002","article-title":"Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: past, present, and future","volume":"112S","author":"Jalali","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"issue":"5","key":"10.1016\/j.cct.2025.107816_bb0260","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/09595230801956165","article-title":"How large must a treatment effect be before it matters to practitioners? An estimation method and demonstration","volume":"27","author":"Miller","year":"2008","journal-title":"Drug Alcohol. Rev."},{"key":"10.1016\/j.cct.2025.107816_bb0265","article-title":"Braeburn news update","author":"Colleen","year":"2020","journal-title":"Braeburn"},{"issue":"4","key":"10.1016\/j.cct.2025.107816_bb0270","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/ajad.12527","article-title":"Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders","volume":"26","author":"Williams","year":"2017","journal-title":"Am. J. Addict."},{"issue":"110","key":"10.1016\/j.cct.2025.107816_bb0275","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019","author":"Krawczyk","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.cct.2025.107816_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108338","article-title":"Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the HEALing communities study","volume":"217","author":"Lefebvre","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.cct.2025.107816_bb0285","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.5439","article-title":"Implementation facilitation to promote emergency department\u2013initiated buprenorphine for opioid use disorder","volume":"6","author":"D\u2019Onofrio","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.cct.2025.107816_bb0290","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.6108","article-title":"Incidence of precipitated withdrawal during a multisite emergency department\u2013initiated buprenorphine clinical trial in the era of fentanyl","volume":"6","author":"D\u2019Onofrio","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cct.2025.107816_bb0295","doi-asserted-by":"crossref","unstructured":"Hayes BT, Favaro J, Behrends CN, Coello D, Jakubowski A, Fox AD. NEXT: description, rationale, and evaluation of a novel internet-based mail-delivered syringe service program. J. Subst. Abus. 2022;0(0):1\u20137. doi:https:\/\/doi.org\/10.1080\/14659891.2022.2144500.","DOI":"10.1080\/14659891.2022.2144500"},{"issue":"7","key":"10.1016\/j.cct.2025.107816_bb0300","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-dose buprenorphine induction in the emergency Department for Treatment of opioid use disorder","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.cct.2025.107816_bb0305","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.annemergmed.2021.05.024","article-title":"Rapid adoption of low-threshold buprenorphine treatment at California emergency departments participating in the CA bridge program","volume":"78","author":"Snyder","year":"2021","journal-title":"Ann. Emerg. Med."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425000102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425000102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:35:07Z","timestamp":1777361707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425000102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":59,"alternative-id":["S1551714425000102"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.107816","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD)","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.107816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107816"}}